ACTIMIS Post-hoc Results on Imaging Stroke Data Using Artificial Intelligence Reinforces Glenzocimab Mode of Action in Stroke Patients

Acticor Biotech announced today the results of its collaboration with Brainomix Limited, to further explore the imaging data using Artificial Intelligence (AI) from its phase 1b/2a ACTIMIS study.

Acticor Biotech is a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies.

The ACTIMIS clinical trial evaluating glenzocimab in combination with the reference treatment (thrombolysis with or without thrombectomy) in patients presenting with Acute Ischemic Stroke (AIS) has demonstrated a favorable safety profile of glenzocimab, as well as a significant reduction in the number of intracerebral hemorrhages and mortality in the group treated with glenzocimab.

To explore the mode of action of glenzocimab in the reduction of intracranial hemorrhage occurrence, a collaboration has been setup with Brainomix, a UK company specialized in the creation of AI-powered imaging biomarkers, to further analyze imaging stroke results from ACTIMIS study.

Study results

In a post-hoc analysis of the ACTIMIS study results, ischemic injury and hemorrhagic transformation volume measurements were quantified using AI-enabled Brainomix software. This provided an objective assessment of the evolution of the stroke brain injury which was associated with clinical outcome. First results using these biomarkers showed that patients treated with glenzocimab had smaller stroke lesion volumes compared to placebo-recipients (standard of care only), mainly due to a significant reduction in hemorrhagic transformation volumes. The benefit of glenzocimab was more pronounced in patients having undergone a mechanical thrombectomy after an initial treatment by a thrombolytic agent.


Yannick PLETAN, Chief Medical Officer and General Manager of Acticor Biotech, explained: “We are delighted with this collaboration with Brainomix, which enables us for the first time to analyze in greater detail the brain images of patients in the ACTIMIS study. Preliminary results seem to show that glenzocimab not only reduces the occurrence of intracranial hemorrhages, but also their volume, compared with placebo. These results support the first analyses of the ACTIMIS study and will be submitted for publication at upcoming international congresses.”
George HARSTON, Chief Medical Officer of Brainomix and Consultant Stroke Physician said: “We are excited to have partnered with Acticor Biotech to support this innovative analysis of the ACTIMIS study using our AI-powered imaging biomarkers. The Brainomix core lab analysis has helped elucidate the mechanism and demonstrate efficacy of glenzocimab. It has shown that glenzocimab reduced brain injury following thrombolysis in stroke, and identified subgroups of patients who appear to benefit most.”

Related Post


Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke, lung fibrosis, and cancer. With origins as a spin-out from the University of Oxford, Brainomix is an expanding commercial-stage company that has innovated award-winning imaging biomarkers and software solutions that are used in more than 30 countries worldwide and in multiple clinical trials for patient selection and AI core lab analysis. Its first product, the Brainomix 360 platform, provides clinicians with the most comprehensive stroke imaging solution, driving faster treatment times and improving functional independence for patients.

Innovation Newsletter
Don't miss the most important news about Innovation. Sign up to receive them by email.


Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), which is aiming to develop an innovative treatment for cardiovascular emergencies, including ischemic stroke.
The positive results from its Phase 1b/2a study, ACTIMIS, confirmed the safety profile and showed a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group in patients with stroke. The efficacy of glenzocimab is now being evaluated in an international Phase 2/3 study, ACTISAVE, which will include 1,000 patients. In July 2022, Acticor Biotech was granted “PRIME” status by the European Medicines Agency (EMA) for glenzocimab in the treatment of stroke. This designation will allow the company to strengthen its interactions and obtain early dialogues with regulatory authorities.
Acticor Biotech is supported by a panel of European and international investors.

Innovation Newsletter
Don't miss the most important news about Innovation. Sign up to receive them by email.

Recent Posts

Revolutionizing Education with Custom E-Learning Solutions – Acadecraft

Acadecraft, a leading provider of comprehensive learning solutions, is redefining the education landscape with the introduction of its custom elearning…

4 hours ago

Publishers Newswire announces its semi-annual ‘Books to Bookmark’ List for Dec. 2023 – 8 Books You’ve Likely Never Seen Before

TEMECULA, Calif., Dec. 8, 2023 (SEND2PRESS NEWSWIRE) — Publishers Newswire (PNW), a news publisher covering books, music and software launched…

8 hours ago

Anicette Stucco LLC Elevates Craftsmanship with Unparalleled Stucco Repair Services

Anicette Stucco LLC, a renowned leader in the construction and stucco industry, proudly announces the expansion of its portfolio with…

1 day ago

Melodius for Creators: Launching World-First Music E-tech Marketplace

Melodius,  pioneering the music education landscape, is proud to announce the launch of a groundbreaking two-sided marketplace designed for creators.…

1 day ago

New certification applies proven science to tobacco cessation treatment

​​DALLAS, December 7, 2023 — The Tobacco Endgame — the path to ending tobacco use and nicotine addiction in the U.S.…

2 days ago

Lock your digital assets and Earn Passive Income

Decentralized finance Also Known As DeFi is an emerging model for organizing and enabling cryptocurrency-based transactions, exchanges, and financial services.…

2 days ago


Innovation Newsletter
Don't miss the most important news about Innovation. Sign up to receive them by email.